These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 9242556

  • 1. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
    Dibenedetto SP, Lo Nigro L, Mayer SP, Rovera G, Schilirò G.
    Blood; 1997 Aug 01; 90(3):1226-32. PubMed ID: 9242556
    [Abstract] [Full Text] [Related]

  • 2. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.
    Panzer-Grümayer ER, Schneider M, Panzer S, Fasching K, Gadner H.
    Blood; 2000 Feb 01; 95(3):790-4. PubMed ID: 10648387
    [Abstract] [Full Text] [Related]

  • 3. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U, Harms DO, Schlüter S, Jorch N, Spaar HJ, Nürnberger W, Völpel S, Gutjahr P, Schrappe M, Janka G, Kabisch H.
    Klin Padiatr; 2000 Feb 01; 212(4):169-73. PubMed ID: 10994545
    [Abstract] [Full Text] [Related]

  • 4. PCR-heteroduplex analysis of TCR gamma, delta and TAL-1 deletions in T-acute lymphoblastic leukemias: implications in the detection of minimal residual disease.
    Nirmala K, Rajalekshmy KR, Raman SG, Shanta V, Rajkumar T.
    Leuk Res; 2002 Apr 01; 26(4):335-43. PubMed ID: 11839375
    [Abstract] [Full Text] [Related]

  • 5. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
    Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, Sandlund JT, Rivera GK, Rubnitz JE, Ribeiro RC, Pui CH, Campana D.
    Blood; 2000 Oct 15; 96(8):2691-6. PubMed ID: 11023499
    [Abstract] [Full Text] [Related]

  • 6. Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia.
    Tutor O, Díaz MA, Ramírez M, Algara P, Madero L, Martínez P.
    Leuk Res; 2002 Sep 15; 26(9):817-20. PubMed ID: 12127556
    [Abstract] [Full Text] [Related]

  • 7. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
    Tzortzatou-Stathopoulou F, Papadopoulou AL, Moschovi M, Botsonis A, Tsangaris GT.
    J Pediatr Hematol Oncol; 2001 Dec 15; 23(9):591-7. PubMed ID: 11902303
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. T cell receptor gamma (TCRG) gene rearrangements in T cell acute lymphoblastic leukemia refelct 'end-stage' recombinations: implications for minimal residual disease monitoring.
    Szczepański T, Langerak AW, Willemse MJ, Wolvers-Tettero IL, van Wering ER, van Dongen JJ.
    Leukemia; 2000 Jul 15; 14(7):1208-14. PubMed ID: 10914544
    [Abstract] [Full Text] [Related]

  • 11. Detection of T cell receptor delta gene rearrangements in childhood B and T lineage acute lymphoblastic leukaemia by southern blot and PCR: technical comparison of two methods of analysis.
    Valetto A, Di Martino D, Scuderi F, Lanza T, Lanciotti M, Bottini F, Dini G.
    Clin Lab Haematol; 2000 Oct 15; 22(5):263-9. PubMed ID: 11122266
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Kinetics of minimal residual disease during induction/consolidation therapy in standard-risk adult B-lineage acute lymphoblastic leukemia.
    Scholten C, Födinger M, Mitterbauer M, Laczika K, Mitterbauer G, Haas OA, Knöbl P, Schwarzinger I, Thalhammer R, Purtscher B.
    Ann Hematol; 1995 Oct 15; 71(4):155-60. PubMed ID: 7578520
    [Abstract] [Full Text] [Related]

  • 16. [The presence of minimal residual disease during induction therapy is a reliable factor for the prognosis of recurrence in children with standard-risk B-cell precursor acute lymphoblastic leukemia].
    Tutor-Ureta O, Díaz MA, Algara P, Madero L, Martínez P.
    Med Clin (Barc); 1999 Jul 03; 113(4):129-31. PubMed ID: 10472597
    [Abstract] [Full Text] [Related]

  • 17. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
    Chan DW, Liang R, Kwong YL, Chan V.
    Am J Hematol; 1996 Jul 03; 52(3):171-7. PubMed ID: 8756082
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long-term follow-up of minimal residual disease in childhood acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers.
    Kuang S, Gu L, Dong S, Cao Q, Xu C, Huang W, Su XY, Huang QH, Xie JX, Chen SJ, Chen Z.
    Cancer Genet Cytogenet; 1996 Jun 03; 88(2):110-7. PubMed ID: 8640718
    [Abstract] [Full Text] [Related]

  • 20. T-cell acute lymphoblastic leukemia relapsing as acute myelogenous leukemia.
    Mantadakis E, Danilatou V, Stiakaki E, Paterakis G, Papadhimitriou S, Kalmanti M.
    Pediatr Blood Cancer; 2007 Mar 03; 48(3):354-7. PubMed ID: 16206214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.